PE20190178A1 - Constructos de alfavirus vivo atenuado y metodos y usos de los mismos - Google Patents
Constructos de alfavirus vivo atenuado y metodos y usos de los mismosInfo
- Publication number
- PE20190178A1 PE20190178A1 PE2018001927A PE2018001927A PE20190178A1 PE 20190178 A1 PE20190178 A1 PE 20190178A1 PE 2018001927 A PE2018001927 A PE 2018001927A PE 2018001927 A PE2018001927 A PE 2018001927A PE 20190178 A1 PE20190178 A1 PE 20190178A1
- Authority
- PE
- Peru
- Prior art keywords
- alphavirus
- ires
- live attenuated
- alfavirus
- constructs
- Prior art date
Links
- 230000002238 attenuated effect Effects 0.000 title abstract 4
- 241000710929 Alphavirus Species 0.000 abstract 5
- 108091026890 Coding region Proteins 0.000 abstract 2
- 241000255925 Diptera Species 0.000 abstract 2
- 108091027544 Subgenomic mRNA Proteins 0.000 abstract 2
- 101710159910 Movement protein Proteins 0.000 abstract 1
- 101710144117 Non-structural protein 4 Proteins 0.000 abstract 1
- 241000709664 Picornaviridae Species 0.000 abstract 1
- 101800001758 RNA-directed RNA polymerase nsP4 Proteins 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000003362 replicative effect Effects 0.000 abstract 1
- 210000003705 ribosome Anatomy 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36161—Methods of inactivation or attenuation
- C12N2770/36162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662316264P | 2016-03-31 | 2016-03-31 | |
| PCT/US2017/024450 WO2017172698A1 (en) | 2016-03-31 | 2017-03-28 | Live, attenuated alphavirus constructs and methods and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190178A1 true PE20190178A1 (es) | 2019-02-01 |
Family
ID=58501809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001927A PE20190178A1 (es) | 2016-03-31 | 2017-03-28 | Constructos de alfavirus vivo atenuado y metodos y usos de los mismos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20190106682A1 (enExample) |
| EP (1) | EP3436062A1 (enExample) |
| JP (1) | JP2019509750A (enExample) |
| KR (1) | KR20180135913A (enExample) |
| CN (1) | CN109195625A (enExample) |
| AU (1) | AU2017241669A1 (enExample) |
| BR (1) | BR112018069079A2 (enExample) |
| CA (1) | CA3019536A1 (enExample) |
| CO (1) | CO2018010359A2 (enExample) |
| CR (1) | CR20180457A (enExample) |
| DO (1) | DOP2018000209A (enExample) |
| EC (1) | ECSP18081582A (enExample) |
| MX (1) | MX2018011839A (enExample) |
| PE (1) | PE20190178A1 (enExample) |
| PH (1) | PH12018502120A1 (enExample) |
| SG (1) | SG11201808479VA (enExample) |
| WO (1) | WO2017172698A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020024292A2 (pt) * | 2018-06-06 | 2021-03-02 | Massachusetts Institute Of Technology | rna circular para translação em células eucarióticas |
| CN110213711B (zh) * | 2019-04-22 | 2021-06-18 | 腾讯科技（深圳）有限公司 | 一种常驻点的估计方法、装置、设备和介质 |
| CN114561366B (zh) * | 2022-03-30 | 2023-06-20 | 西南民族大学 | 一种山羊库布病毒分离株及其应用 |
| US12297285B2 (en) | 2022-06-24 | 2025-05-13 | Orna Therapeutics, Inc. | Circular RNA encoding chimeric antigen receptors targeting BCMA |
| CN117925540B (zh) * | 2024-03-22 | 2024-06-18 | 北京昭衍新药研究中心股份有限公司 | 一种cv2117-hav-htlv-2多基因假病毒及其制备方法和应用 |
| CN118127077B (zh) * | 2024-05-08 | 2024-07-16 | 南京农业大学三亚研究院 | 基于盖塔病毒骨架的嵌合甲病毒制备方法和应用 |
| KR102864666B1 (ko) * | 2025-04-21 | 2025-09-29 | 대한민국 | 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050112095A1 (en) * | 2002-07-09 | 2005-05-26 | Tsu-An Hsu | Internal ribosome entry sites for recombinant protein expression |
| KR101668849B1 (ko) * | 2008-01-24 | 2016-10-24 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도 |
-
2017
- 2017-03-28 CA CA3019536A patent/CA3019536A1/en not_active Abandoned
- 2017-03-28 EP EP17716083.5A patent/EP3436062A1/en not_active Withdrawn
- 2017-03-28 CR CR20180457A patent/CR20180457A/es unknown
- 2017-03-28 WO PCT/US2017/024450 patent/WO2017172698A1/en not_active Ceased
- 2017-03-28 CN CN201780032818.3A patent/CN109195625A/zh active Pending
- 2017-03-28 AU AU2017241669A patent/AU2017241669A1/en not_active Abandoned
- 2017-03-28 KR KR1020187031480A patent/KR20180135913A/ko not_active Ceased
- 2017-03-28 BR BR112018069079A patent/BR112018069079A2/pt not_active IP Right Cessation
- 2017-03-28 US US16/088,815 patent/US20190106682A1/en not_active Abandoned
- 2017-03-28 MX MX2018011839A patent/MX2018011839A/es unknown
- 2017-03-28 PE PE2018001927A patent/PE20190178A1/es unknown
- 2017-03-28 SG SG11201808479VA patent/SG11201808479VA/en unknown
- 2017-03-28 JP JP2018551252A patent/JP2019509750A/ja not_active Withdrawn
-
2018
- 2018-09-27 CO CONC2018/0010359A patent/CO2018010359A2/es unknown
- 2018-09-28 DO DO2018000209A patent/DOP2018000209A/es unknown
- 2018-10-01 PH PH12018502120A patent/PH12018502120A1/en unknown
- 2018-10-30 EC ECSENADI201881582A patent/ECSP18081582A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180135913A (ko) | 2018-12-21 |
| ECSP18081582A (es) | 2019-02-28 |
| SG11201808479VA (en) | 2018-10-30 |
| CO2018010359A2 (es) | 2018-12-14 |
| AU2017241669A1 (en) | 2018-11-22 |
| CN109195625A (zh) | 2019-01-11 |
| EP3436062A1 (en) | 2019-02-06 |
| PH12018502120A1 (en) | 2019-07-15 |
| DOP2018000209A (es) | 2019-01-31 |
| CA3019536A1 (en) | 2017-10-05 |
| CR20180457A (es) | 2019-04-09 |
| US20190106682A1 (en) | 2019-04-11 |
| BR112018069079A2 (pt) | 2019-01-29 |
| JP2019509750A (ja) | 2019-04-11 |
| MX2018011839A (es) | 2019-05-23 |
| WO2017172698A1 (en) | 2017-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190178A1 (es) | Constructos de alfavirus vivo atenuado y metodos y usos de los mismos | |
| CO2018005258A2 (es) | Vacuna del virus herpes simple | |
| CO2018005229A2 (es) | Vacuna de virus sincitial respiratorio | |
| CO2021006362A2 (es) | Construcciones de ácido nucleico y métodos de uso | |
| CO2018005265A2 (es) | Vacunas de ácido nucleico para el virus varicela-zóster | |
| CL2019002805A1 (es) | Expresión selectiva de un transgene de tejidos. | |
| CL2018000587A1 (es) | Adenovirus oncolítico que codifica una proteína b7 (divisional de sol. n° 2731-2017) | |
| EA201891415A8 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения | |
| MX2018007860A (es) | Vacunas recombinantes contra el zika. | |
| AR102006A1 (es) | Vacunas recombinantes contra el virus de la fiebre aftosa (fmdv) y sus usos | |
| MX2019004593A (es) | Vectores recombinantes que expresan antigenos de virus de influenza aviar y usos de los mismos. | |
| MX2016011537A (es) | Metodos y composiciones para aumentar una relacion de celulas t efectoras con respecto a las celulas t reguladoras. | |
| MX378503B (es) | Alfavirus recombinantes atenuados incapaces de replicarse en mosquitos y usos de estos. | |
| MY189334A (en) | Lentiviral vector-based japanese encephalitis immunogenic composition | |
| MX382535B (es) | Proteinas de fusion fmdv y e2 y usos de ellos. | |
| WO2012065105A3 (en) | Chimeric flavivirus vaccines | |
| EA202191147A1 (ru) | Вакцина виб h52 с гетерологичным шиповидным белком | |
| MX2018012858A (es) | Metodo mejorado para producir particulas similares a virus. | |
| MY209232A (en) | Transmitter and repetition method thereof | |
| BR112019008584A2 (pt) | vacinas de mosaico para vírus de doença de pé-e-boca de sorotipo a | |
| AR110609A1 (es) | Plantas modificadas genéticamente que comprenden genes de tolerancia al estrés por sequía | |
| MX2018006500A (es) | Virus vivo que tiene un banco de cepas atenuadas del virus del dengue, y una vacuna contra el dengue que contiene el mismo como antigenos. | |
| AR119078A2 (es) | Polinucleótido recombinante aislado; célula vegetal transgénica aislada, incapaz de generar un individuo completo; construcción de adn aislada; composición agrícola; y método para controlar una población de plagas de insectos | |
| EA202191862A2 (ru) | Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения | |
| AR105431A1 (es) | Vacunas para enfermedades infecciosas |